SP-0586: Radiotherapy supports tumour-specific immunity

Radiotherapy supports protective tumor-specific immunity

Radiotherapy is an important therapeutic option for the treatment of cancer. Growing evidence indicates that, besides inducing an irreversible DNA damage, radiotherapy promotes tumor-specific immune response, which significantly contribute to therapeutic efficacy. We postulate that radiotherapy activates tumor-associated dendritic cells, thus changing the tolerogenic tumor environment into an i...

Exosomes in tumour immunity

In preclinical studies, dc-derived exosomes administered as prophylactic 9 or therapeutic 5 cancer vaccines demonstrated their value as potent immune-activating agents, often more so than did live dcs. Based on this premise, some phase i trials of dc-exosomes have been conducted, showing promising results in very testing clinical scenarios, such as advanced non-small-cell lung cancer 10. Why dc...

Tumour viruses and innate immunity.

Host cells sense viral infection through pattern recognition receptors (PRRs), which detect pathogen-associated molecular patterns (PAMPs) and stimulate an innate immune response. PRRs are localized to several different cellular compartments and are stimulated by viral proteins and nucleic acids. PRR activation initiates signal transduction events that ultimately result in an inflammatory respo...

Hyperbaric oxygenation for tumour sensitisation to radiotherapy.

BACKGROUND Cancer is a common disease and radiotherapy is one well-established treatment for some solid tumours. Hyperbaric oxygenation therapy (HBOT) may improve the ability of radiotherapy to kill hypoxic cancer cells, so the administration of radiotherapy while breathing hyperbaric oxygen may result in a reduction in mortality and recurrence. OBJECTIVES To assess the benefits and harms of ...

The role of macrophages in tumour immunity.